We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant Pharmaceuticals will pay up to $445 million for the rights to AstraZeneca’s investigational psoriasis drug brodalumab, which is set for regulatory submissions in the U.S. and EU in the fourth quarter. Read More
EU biopharma groups have lodged a complaint with the European Commission opposing a French law that promotes off-label use of medicines, saying it put cost ahead of patient safety. Read More
The FDA has granted priority review for Bristol-Myers Squibb and AbbVie’s Empliciti for the treatment of multiple myeloma in patients who have received one or more previous therapies — giving it a PDUFA date of Feb. 29, 2016. Read More
The European Medicines Agency’s medical literature monitoring service kicked into full operation Tuesday, allowing drugmakers to easily search for information on adverse reactions associated with their products. Read More
Eli Lilly continued to beat back court challenges against Cymbalta, as a Virginia jury on Tuesday found the drugmaker not negligent in marketing its blockbuster antidepressant. Read More
Actavis must remove its generic version of Endo’s noncrush-resistant painkiller Opana from the U.S. market by Oct. 13, a New York federal judge ruled Aug. 14, citing infringement of Opana’s patents. Read More
Mylan scored a potential win from the U.S. Patent and Trademark Office when it agreed to review challenges to two patents on Teva’s blockbuster multiple schlerosis drug Copaxone. Read More